<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05096455</url>
  </required_header>
  <id_info>
    <org_study_id>LOCAL/2021/SB-01</org_study_id>
    <nct_id>NCT05096455</nct_id>
  </id_info>
  <brief_title>Hypertriglyceridemia Associated Acute Pancreatitis in Intensive Care Unit and Therapeutic Plasmapheresis</brief_title>
  <acronym>TRIPAN</acronym>
  <official_title>Hypertriglyceridemia Associated Acute Pancreatitis in Intensive Care Unit and Therapeutic Plasmapheresis: a Multicenter Retrospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute pancreatitis (AP) is a one of the potentially life-threatening complication of severe&#xD;
      hypertriglyceridemia (HTG), with mortality around to 30%.&#xD;
&#xD;
      HTG-associated PA and their complications management has to be the same as the other&#xD;
      pancreatitis, but they are associated with the worse clinical outcomes. Triglycerides levels&#xD;
      are correlated with the risk of pancreatitis and severity.&#xD;
&#xD;
      Therapeutic plasma exchange (TPE) could provide positive effects in reducing triglyceridemia&#xD;
      plasma levels during the acute phase of HTG-AP, and in prevention of recurrence. There is&#xD;
      currently no difference about mortality in studies. Some authors have recommended its use&#xD;
      only in severe HTG-AP and have precised the need of early initiation to have positive&#xD;
      results.&#xD;
&#xD;
      Despite such promising findings from studies, the effects of therapeutic plasma exchange on&#xD;
      HTG-associated PA have never been specifically assessed and its benefits in critically ill&#xD;
      patients with AP remains uncertain.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2010</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality at Day 28</measure>
    <time_frame>Day 28</time_frame>
    <description>Assess the factors on admission associated with the prognosis of patients admitted in ICU for HTG-associated PA.&#xD;
Factors associated with death at D28 will be considered individually for entry into a multivariate model. The following variables of interest will be tested in the model: SOFA score, triglyceride level at admission, obesity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of hospitalization</measure>
    <time_frame>Day 28</time_frame>
    <description>Describe length of stay in ICU and on hospital for patients admitted in ICU for HTG-associated PA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of organ support</measure>
    <time_frame>Day 28</time_frame>
    <description>Describe use of organ supports (vasopressors, extra-renal dialysis and mechanical ventilation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess benefit of plasmapheresis</measure>
    <time_frame>Day 28</time_frame>
    <description>Assess benefit of plasmapheresis for patients admitted in ICU for HTG-associated PA</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">100</enrollment>
  <condition>Pancreatitis</condition>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>severe acute pancreatitis</arm_group_label>
    <description>Patients 18 years of age or older admitted to intensive care or resuscitation for severe acute pancreatitis (AP) with hypertriglyceridemia (HTG)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Any patient hospitalized with severe acute pancreatitis of hypertriglycemic origin admitted&#xD;
        to the ICU between January 2010 and January 2020.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Admission in ICU for acute pancreatitis associated with HTG&#xD;
&#xD;
        Exclusion Criteria : Patient without norepinephrine or missing data.&#xD;
&#xD;
          -  Acute pancreatitis without HTG&#xD;
&#xD;
          -  Patient already include in this study&#xD;
&#xD;
          -  Patient opposed to use of his data&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>stephanie Bulyez, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nîmes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Nîmes - Hôpital Universitaire Carémeau</name>
      <address>
        <city>Nîmes Cedex 09</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 15, 2021</study_first_submitted>
  <study_first_submitted_qc>October 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2021</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ICU</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

